Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...
Researchers at The Institute of Cancer Research have found a dual genetic test is more accurate than the traditional approach in identifying multiple myeloma patients who may be at an elevated risk of ...
The novel Cleavage High-throughput Assay (CHiTA) developed at Penn State provides a scarless method to characterize thousands of diverse small self-cleaving RNA enzymes, called twister ribozymes, in a ...
Patients who have had a VUS through NGS that is predicted to cause abnormal splicing. Patients who want to prepare for prenatal/pre-implantation diagnosis and for predictive testing for individuals at ...
LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today ...
Dr. Kayvan Zainabadi (center) is working with colleagues in Pune, India, to test the RNA-based TB diagnostic he is developing. From left: Dr. Mandar Paradkar (co-PI, pediatrician), Vidyulata Kamble, ...
Promega, a global manufacturer of reagents, assays and benchtop instruments essential for COVID-19 research, drug development and diagnostic testing, including RNA extraction, increased production ...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results